Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDAH1 | O94760 | 2/20 | 0.53 |
| ▸ | GSR | P00390 | 1/20 | 0.50 |
| ▸ | ARG2 | P78540 | 4/20 | 0.46 |
| ▸ | ARG1 | P05089 | 3/20 | 0.46 |
| ▸ | NOS2 | P35228 | 6/20 | 0.45 |
| ▸ | NOS1 | P29475 | 5/20 | 0.45 |
| ▸ | NOS3 | P29474 | 4/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14508685 | 0.95 | DDAH1 (0.54) | DDAH1GSRARG2ARG1NOS2 | |
| SCHEMBL25660441 | 0.89 | DDAH1 (0.58) | DDAH1GSRARG2ARG1NOS2 | |
| SCHEMBL25661125 | 0.89 | DDAH1 (0.58) | DDAH1GSRARG2ARG1NOS2 | |
| SCHEMBL25357433 | 0.87 | DDAH1 (0.57) | DDAH1GSRARG2ARG1NOS2 | |
| SCHEMBL25357429 | 0.87 | DDAH1 (0.57) | DDAH1GSRARG2ARG1NOS2 | |
| SCHEMBL30508517 | 0.87 | NOS3 (0.57) | DDAH1GSRNOS2NOS1NOS3 | |
| Lysine SCHEMBL28931663 | 0.84 | GSR (0.59) | DDAH1GSRARG2ARG1NOS2 | |
| SCHEMBL21261918 | 0.84 | DDAH1 (0.46) | DDAH1GSRARG2ARG1NOS2 | |
| SCHEMBL21261917 | 0.84 | DDAH1 (0.46) | DDAH1GSRARG2ARG1NOS2 | |
| SCHEMBL29392211 | 0.84 | NOD1 (0.51) | DDAH1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170281785-A1 | GLYCEROL LINKED PEGYLATED SUGARS AND GLYCOPEPTIDES | NOVO NORDISK A/S (DK) | 2017-10-05 | — | — | US | disclosed |
| US-9187546-B2 | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants | NOVO NORDISK A/S (DK) | 2015-11-17 | — | — | US | disclosed |
| US-9187532-B2 | Glycosylation of peptides via O-linked glycosylation sequences | NOVO NORDISK A/S (DK) | 2015-11-17 | — | — | US | disclosed |
| US-20150258206-A1 | GLYCEROL LINKED PEGYLATED SUGARS AND GLYCOPEPTIDES | NOVO NORDISK AS (DK) | 2015-09-17 | — | — | US | disclosed |
| US-9050304-B2 | Methods of treatment using glycopegylated G-CSF | RATIOPHARM GMBH (DE) | 2015-06-09 | — | — | US | disclosed |
| US-9029331-B2 | Glycopegylated granulocyte colony stimulating factor | NOVO NORDISK A/S (DK) | 2015-05-12 | — | — | US | disclosed |
| US-20150111245-A1 | GLYCOPEGYLATED FOLLICLE STIMULATING HORMONE | NOVO NORDISK AS (DK) | 2015-04-23 | — | — | US | disclosed |
| US-8916360-B2 | Glycopegylated erythropoietin | NOVO NORDISK A/S (DK) | 2014-12-23 | — | — | US | disclosed |
| US-8911967-B2 | One pot desialylation and glycopegylation of therapeutic peptides | NOVO NORDISK A/S (DK) | 2014-12-16 | — | — | US | disclosed |
| US-8633157-B2 | Glycopegylated erythropoietin | NOVO NORDISK A/S (DK) | 2014-01-21 | — | — | US | disclosed |
| US-20080242846-A1 | O-LINKED GLYCOSYLATION OF PEPTIDES | NEOSE TECHNOLOGIES, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| US-20080242607-A1 | GLYCOSYLATION OF PEPTIDES VIA O-LINKED GLYCOSYLATION SEQUENCES | NEOSE TECHNOLOGIES, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| US-7405198-B2 | Glycopegylated erythropoietin | NEOSE TECHNOLOGIES, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20080146782-A1 | GLYCEROL LINKED PEGYLATED SUGARS AND GLYCOPEPTIDES | NEOSE TECHNOLOGIES, INC. (US) | 2008-06-19 | — | — | US | disclosed |
| US-7338933-B2 | Human Growth Hormone polypeptide comprising an O-linked glycosylation site that does not exist in a wild type polypeptide; glycoconjugates in which a species such as a water-soluble polymer, a therapeutic agent or a biomolecule is covalently linked through the site | NEOSE TECHNOLOGIES, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-20080015142-A1 | Glycopegylated Follicle Stimulating Hormone | NOVO NORDISK A/S (DK) | 2008-01-17 | — | — | US | disclosed |
| US-20070254834-A1 | Glycopegylated Erythropoietin | NOVO NORDISK A/S (DK) | 2007-11-01 | — | — | US | disclosed |
| US-20070254836-A1 | Glycopegylated Granulocyte Colony Stimulating Factor | NOVO NORDISK A/S (DK) | 2007-11-01 | — | — | US | disclosed |
| US-20070154992-A1 | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants | NEOSE TECHNOLOGIES, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070014759-A1 | Glycopegylated granulocyte colony stimulating factor | NEOSE TECHNOLOGIES, INC. (US) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146782-A1 | GLYCEROL LINKED PEGYLATED SUGARS AND GLYCOPEPTIDES | UGCG, B3GAT3, UGGT1 | DDAH1 3339/4885GSR 735/4885ARG2 2334/4885 |
| US-20080242846-A1 | O-LINKED GLYCOSYLATION OF PEPTIDES | OGA, OGT, OSTC | DDAH1 2574/4885GSR 3163/4885ARG2 1134/4885 |
| US-20070254834-A1 | Glycopegylated Erythropoietin | EPOR, UGGT1, GNE | DDAH1 3487/4885GSR 1313/4885ARG2 2111/4885 |
| US-20070254836-A1 | Glycopegylated Granulocyte Colony Stimulating Factor | CSF3R, GMFG, GALNT1 | DDAH1 3327/4885GSR 1649/4885ARG2 1370/4885 |
| US-20080242607-A1 | GLYCOSYLATION OF PEPTIDES VIA O-LINKED GLYCOSYLATION SEQUENCES | NGLY1, OGA, OGT | DDAH1 2728/4885GSR 4072/4885ARG2 1967/4885 |
| US-20070014759-A1 | Glycopegylated granulocyte colony stimulating factor | CSF3R, GMFG, GALNT1 | DDAH1 3327/4885GSR 1649/4885ARG2 1370/4885 |
| US-20150111245-A1 | GLYCOPEGYLATED FOLLICLE STIMULATING HORMONE | FSHR, SHBG, GNRHR | DDAH1 2074/4885GSR 1389/4885ARG2 3499/4885 |
| US-20170281785-A1 | GLYCEROL LINKED PEGYLATED SUGARS AND GLYCOPEPTIDES | UGCG, B3GAT3, UGGT1 | DDAH1 3339/4885GSR 735/4885ARG2 2334/4885 |
| US-20070154992-A1 | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants | GHITM, PTMS, GHRHR | DDAH1 1833/4885GSR 4263/4885ARG2 4443/4885 |
| US-20150258206-A1 | GLYCEROL LINKED PEGYLATED SUGARS AND GLYCOPEPTIDES | UGCG, B3GAT3, UGGT1 | DDAH1 3339/4885GSR 735/4885ARG2 2334/4885 |
| US-20080015142-A1 | Glycopegylated Follicle Stimulating Hormone | FSHR, GNRHR, SHBG | DDAH1 2133/4885GSR 1367/4885ARG2 3360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.